Erin, N. Et Al. 2020. CD200 mimetic aptamer PEG-M49 markedly increases the therapeutic effects of pegylated liposomal doxorubicin in a mouse model of metastatic breast carcinoma: an effect independent of CD200 receptor 1.. Cancer immunology, immunotherapy : CII , vol.69 , 103-114.

Erin, N., Dilmaç, S., CURRY, A., Duymuş, Ö., Tanriover, G., Prodeus, A., ... Gariepy, J.(2020). CD200 mimetic aptamer PEG-M49 markedly increases the therapeutic effects of pegylated liposomal doxorubicin in a mouse model of metastatic breast carcinoma: an effect independent of CD200 receptor 1.. Cancer immunology, immunotherapy : CII , vol.69, 103-114.

Erin, NURAY Et Al. "CD200 mimetic aptamer PEG-M49 markedly increases the therapeutic effects of pegylated liposomal doxorubicin in a mouse model of metastatic breast carcinoma: an effect independent of CD200 receptor 1.," Cancer immunology, immunotherapy : CII , vol.69, 103-114, 2020

Erin, NURAY Et Al. "CD200 mimetic aptamer PEG-M49 markedly increases the therapeutic effects of pegylated liposomal doxorubicin in a mouse model of metastatic breast carcinoma: an effect independent of CD200 receptor 1.." Cancer immunology, immunotherapy : CII , vol.69, pp.103-114, 2020

Erin, N. Et Al. (2020) . "CD200 mimetic aptamer PEG-M49 markedly increases the therapeutic effects of pegylated liposomal doxorubicin in a mouse model of metastatic breast carcinoma: an effect independent of CD200 receptor 1.." Cancer immunology, immunotherapy : CII , vol.69, pp.103-114.

@article{article, author={NURAY ERİN Et Al. }, title={CD200 mimetic aptamer PEG-M49 markedly increases the therapeutic effects of pegylated liposomal doxorubicin in a mouse model of metastatic breast carcinoma: an effect independent of CD200 receptor 1.}, journal={Cancer immunology, immunotherapy : CII}, year=2020, pages={103-114} }